The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Neurodegenerative diseases (NDs) are currently incurable diseases that cause progressive
degeneration of nerve cells. Many of the disease-causing proteins of NDs are “undruggable” …

Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …

Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative
diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the …

TRIM21 (Ro52/SSA1) is an E3 ubiquitin ligase with key roles in immune host defence, signal
transduction, and possibly cell cycle regulation. It is also an autoantibody target in Sjögren's …

In the 20 years since the first report of a proteolysis targeting chimeric (PROTAC) molecule,
targeted protein degradation (TPD) technologies have attempted to revolutionize the fields …

Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

Humans have four IgG antibody subclasses that selectively or differentially engage immune
effector molecules to protect against infections. Although IgG1 has been studied in detail …

The tripartite-motif (TRIM) family represents one of the largest classes of putative single
protein RING-finger E3 ubiquitin ligases. TRIM family is involved in a variety of cellular …

Selective degradation of pathological protein aggregates while sparing monomeric forms is
of major therapeutic interest. The E3 ligase tripartite motif–containing protein 21 (TRIM21) …